Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. August 2023 07:00 ET | Quelle: HilleVax, Inc.

HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
12. Mai 2023 16:05 ET | Quelle: HilleVax, Inc.

HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
09. Mai 2023 07:00 ET | Quelle: HilleVax, Inc.

HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
25. April 2023 06:45 ET | Quelle: HilleVax, Inc.

HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate

Topline safety and clinical efficacy data from NEST-IN1 expected in the first quarter of 2024 HIL-214 is the most advanced vaccine candidate for norovirus infection There are currently no approved...
17. März 2023 16:05 ET | Quelle: HilleVax, Inc.

HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

BOSTON, March 17, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported...
09. Januar 2023 07:00 ET | Quelle: HilleVax, Inc.

HilleVax Announces Executive Management Appointments and Promotions

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
04. Januar 2023 16:05 ET | Quelle: HilleVax, Inc.

HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
05. Dezember 2022 06:30 ET | Quelle: HilleVax, Inc.

HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results...
10. November 2022 18:30 ET | Quelle: HilleVax, Inc.

HilleVax to Participate in November Investor Conferences

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
10. November 2022 16:05 ET | Quelle: HilleVax, Inc.

HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...

Vorherige Seite

Nächste Seite